Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 32 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Natco Pharma's reported carbon emissions
In 2024, Natco Pharma reported total carbon emissions of approximately 70,000,000 kg CO2e, comprising 28,403,250 kg CO2e from Scope 1 and 41,763,620 kg CO2e from Scope 2 emissions, with an additional 60,268,600 kg CO2e attributed to Scope 3 emissions. This marks a notable increase in emissions compared to previous years, where in 2023, the total was about 68,760,000 kg CO2e, with Scope 1 at 20,898,100 kg CO2e and Scope 2 at 39,945,230 kg CO2e. Despite the rising emissions, Natco Pharma has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to disclose its emissions data, which is essential for transparency and accountability in its climate commitments. Overall, Natco Pharma's emissions profile reflects the challenges faced by the pharmaceutical industry in managing carbon footprints while striving for operational efficiency and growth.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Natco Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
